Research
HC Wainwright Starts Ipsen Coverage with Buy Rating
HC Wainwright & Co on Friday initiated coverage of French biopharmaceutical company Ipsen (IPN.PA) with a buy rating and a price target of 215 euros.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
$IPN.PA